ABL1 is altered in 1.04% of non-hodgkin lymphoma patients [2].

ABL1 is an inclusion eligibility criterion in 19 clinical trials for non-hodgkin lymphoma, of which 11 are open and 8 are closed. Of the trials that contain ABL1 status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (6 open) [3].

AFF1 is an inclusion eligibility criterion in 18 clinical trials for non-hodgkin lymphoma, of which 11 are open and 7 are closed. Of the trials that contain AFF1 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (7 open) [3].

AKT1 is altered in 1.43% of non-hodgkin lymphoma patients [2].

AKT1 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain AKT1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

AKT2 is altered in 0.26% of non-hodgkin lymphoma patients [2].

AKT2 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain AKT2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

AKT3 is altered in 1.12% of non-hodgkin lymphoma patients [2].

AKT3 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain AKT3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

ALK is altered in 2.47% of non-hodgkin lymphoma patients [2].

ALK is an inclusion eligibility criterion in 4 clinical trials for non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ALK status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (3 open) [3].

ARAF is altered in 0.79% of non-hodgkin lymphoma patients [2].

ARAF is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ARAF status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

ARID1A is altered in 9.2% of non-hodgkin lymphoma patients [2].

ARID1A is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ARID1A status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].

ASXL1 is altered in 2.08% of non-hodgkin lymphoma patients [2].

ASXL1 is an inclusion eligibility criterion in 4 clinical trials for non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain ASXL1 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), and 2 are phase 2 (2 open) [3].

ATM is altered in 7.97% of non-hodgkin lymphoma patients [2].

ATM is an inclusion eligibility criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain ATM status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].

ATR is altered in 1.54% of non-hodgkin lymphoma patients [2].

ATR is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ATR status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

ATRX is altered in 2.63% of non-hodgkin lymphoma patients [2].

ATRX is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ATRX status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

BARD1 is altered in 0.38% of non-hodgkin lymphoma patients [2].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BARD1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

BCL2 is altered in 16.47% of non-hodgkin lymphoma patients [2].

BCL2 is an inclusion eligibility criterion in 5 clinical trials for non-hodgkin lymphoma, of which 3 are open and 2 are closed. Of the trials that contain BCL2 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [3].

BCL6 is altered in 4.95% of non-hodgkin lymphoma patients [2].

BCL6 is an inclusion eligibility criterion in 5 clinical trials for non-hodgkin lymphoma, of which 3 are open and 2 are closed. Of the trials that contain BCL6 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [3].

BCR is altered in 2.73% of non-hodgkin lymphoma patients [2].

BCR is an inclusion eligibility criterion in 19 clinical trials for non-hodgkin lymphoma, of which 11 are open and 8 are closed. Of the trials that contain BCR status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (6 open) [3].

BRAF is altered in 2.33% of non-hodgkin lymphoma patients [2].

BRAF is an inclusion eligibility criterion in 5 clinical trials for non-hodgkin lymphoma, of which 3 are open and 2 are closed. Of the trials that contain BRAF status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 4 are phase 2 (3 open) [3].

BRCA1 is altered in 1.71% of non-hodgkin lymphoma patients [2].

BRCA1 is an inclusion eligibility criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].

BRCA2 is altered in 2.69% of non-hodgkin lymphoma patients [2].

BRCA2 is an inclusion eligibility criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].

BRIP1 is altered in 1.19% of non-hodgkin lymphoma patients [2].

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BRIP1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

C11orf30 is altered in 2.44% of non-hodgkin lymphoma patients [2].

C11orf30 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain C11orf30 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

CBFA2T3 is altered in 1.43% of non-hodgkin lymphoma patients [2].

CBFA2T3 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CBFB is altered in 0.31% of non-hodgkin lymphoma patients [2].

CBFB is an inclusion eligibility criterion in 6 clinical trials for non-hodgkin lymphoma, of which 3 are open and 3 are closed. Of the trials that contain CBFB status and non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (3 open) [3].

CCND1 is altered in 3.14% of non-hodgkin lymphoma patients [2].

CCND1 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain CCND1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [3].

CCND2 is altered in 0.67% of non-hodgkin lymphoma patients [2].

CCND2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND2 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CCND3 is altered in 5.59% of non-hodgkin lymphoma patients [2].

CCND3 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND3 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CCNE1 is altered in 0.66% of non-hodgkin lymphoma patients [2].

CCNE1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCNE1 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CCNE2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCNE2 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDK12 is altered in 0.94% of non-hodgkin lymphoma patients [2].

CDK12 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain CDK12 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

CDK2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDK2 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDK4 is altered in 0.4% of non-hodgkin lymphoma patients [2].

CDK4 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDK4 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDK6 is altered in 0.72% of non-hodgkin lymphoma patients [2].

CDK6 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDKN1A is altered in 0.49% of non-hodgkin lymphoma patients [2].

CDKN1A is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN1A status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDKN1B is altered in 1.78% of non-hodgkin lymphoma patients [2].

CDKN1B is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN1B status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CDKN2A is altered in 11.85% of non-hodgkin lymphoma patients [2].

CDKN2A is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDKN2A status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CHEK1 is altered in 1.05% of non-hodgkin lymphoma patients [2].

CHEK1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain CHEK1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

CHEK2 is altered in 1.19% of non-hodgkin lymphoma patients [2].

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain CHEK2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

CREBBP is altered in 23.09% of non-hodgkin lymphoma patients [2].

CREBBP is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CREBBP status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CRKL is altered in 0.2% of non-hodgkin lymphoma patients [2].

CRKL is an inclusion eligibility criterion in 5 clinical trials for non-hodgkin lymphoma, of which 4 are open and 1 is closed. Of the trials that contain CRKL status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 4 are phase 2 (3 open) [3].

DDIT3 is altered in 0.26% of non-hodgkin lymphoma patients [2].

DDIT3 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DDIT3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

DEK is an inclusion eligibility criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain DEK status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (5 open) [3].

DNMT3A is altered in 5.79% of non-hodgkin lymphoma patients [2].

DNMT3A is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains DNMT3A status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ELL is an inclusion eligibility criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain ELL status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (6 open) [3].

ERCC2 is altered in 1.29% of non-hodgkin lymphoma patients [2].

ERCC2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

ERCC3 is altered in 0.83% of non-hodgkin lymphoma patients [2].

ERCC3 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

ERCC4 is altered in 1.0% of non-hodgkin lymphoma patients [2].

ERCC4 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC4 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

ERCC5 is altered in 2.16% of non-hodgkin lymphoma patients [2].

ERCC5 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC5 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

ERCC6 is altered in 1.45% of non-hodgkin lymphoma patients [2].

ERCC6 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ERCC6 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

ETV6 is altered in 3.49% of non-hodgkin lymphoma patients [2].

ETV6 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ETV6 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

EWSR1 is altered in 0.27% of non-hodgkin lymphoma patients [2].

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

EZH2 is altered in 8.7% of non-hodgkin lymphoma patients [2].

EZH2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain EZH2 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FANCA is altered in 1.71% of non-hodgkin lymphoma patients [2].

FANCA is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCA status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

FANCB is altered in 2.15% of non-hodgkin lymphoma patients [2].

FANCB is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCB status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

FANCC is altered in 0.92% of non-hodgkin lymphoma patients [2].

FANCC is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCC status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

FANCD2 is altered in 1.0% of non-hodgkin lymphoma patients [2].

FANCD2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCD2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

FANCE is altered in 1.19% of non-hodgkin lymphoma patients [2].

FANCE is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCE status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

FANCF is altered in 1.42% of non-hodgkin lymphoma patients [2].

FANCF is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCF status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

FANCG is altered in 0.24% of non-hodgkin lymphoma patients [2].

FANCG is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCG status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

FANCI is altered in 0.53% of non-hodgkin lymphoma patients [2].

FANCI is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCI status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

FANCL is altered in 0.48% of non-hodgkin lymphoma patients [2].

FANCL is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCL status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

FANCM is altered in 3.23% of non-hodgkin lymphoma patients [2].

FANCM is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain FANCM status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

FGFR1 is altered in 1.23% of non-hodgkin lymphoma patients [2].

FGFR1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR1 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FGFR2 is altered in 1.56% of non-hodgkin lymphoma patients [2].

FGFR2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR2 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FGFR3 is altered in 1.36% of non-hodgkin lymphoma patients [2].

FGFR3 is an inclusion eligibility criterion in 5 clinical trials for non-hodgkin lymphoma, of which 5 are open and 0 are closed. Of the trials that contain FGFR3 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open) and 2 are phase 2 (2 open) [3].

FGFR4 is altered in 0.91% of non-hodgkin lymphoma patients [2].

FGFR4 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR4 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FLT3 is altered in 1.49% of non-hodgkin lymphoma patients [2].

FLT3 is an inclusion eligibility criterion in 20 clinical trials for non-hodgkin lymphoma, of which 11 are open and 9 are closed. Of the trials that contain FLT3 status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 8 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 8 are phase 2 (5 open) [3].

FOXO1 is altered in 6.41% of non-hodgkin lymphoma patients [2].

FOXO1 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains FOXO1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

GLIS2 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains GLIS2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HDAC1 is altered in 0.67% of non-hodgkin lymphoma patients [2].

HDAC1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain HDAC1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

HDAC2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain HDAC2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

HIP1 is altered in 0.27% of non-hodgkin lymphoma patients [2].

HIP1 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HIP1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HOXA9 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HOXA9 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is altered in 0.26% of non-hodgkin lymphoma patients [2].

HRAS is an inclusion eligibility criterion in 5 clinical trials for non-hodgkin lymphoma, of which 3 are open and 2 are closed. Of the trials that contain HRAS status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [3].

IGH is altered in 12.73% of non-hodgkin lymphoma patients [2].

IGH is an inclusion eligibility criterion in 5 clinical trials for non-hodgkin lymphoma, of which 5 are open and 0 are closed. Of the trials that contain IGH status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

IKZF1 is altered in 2.27% of non-hodgkin lymphoma patients [2].

IKZF1 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IKZF1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (0 open) [3].

JAK2 is altered in 2.4% of non-hodgkin lymphoma patients [2].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [3].

KAT6A is altered in 2.36% of non-hodgkin lymphoma patients [2].

KAT6A is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KAT6A status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM5A is altered in 1.76% of non-hodgkin lymphoma patients [2].

KDM5A is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KDM5A status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is altered in 1.3% of non-hodgkin lymphoma patients [2].

KIT is an inclusion eligibility criterion in 6 clinical trials for non-hodgkin lymphoma, of which 3 are open and 3 are closed. Of the trials that contain KIT status and non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (3 open) [3].

KMT2A is altered in 3.58% of non-hodgkin lymphoma patients [2].

KMT2A is an inclusion eligibility criterion in 19 clinical trials for non-hodgkin lymphoma, of which 12 are open and 7 are closed. Of the trials that contain KMT2A status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (7 open) [3].

KRAS is altered in 1.42% of non-hodgkin lymphoma patients [2].

KRAS is an inclusion eligibility criterion in 6 clinical trials for non-hodgkin lymphoma, of which 4 are open and 2 are closed. Of the trials that contain KRAS status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [3].

MAF is altered in 0.56% of non-hodgkin lymphoma patients [2].

MAF is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain MAF status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (3 open) [3].

MAFB is altered in 0.36% of non-hodgkin lymphoma patients [2].

MAFB is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain MAFB status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [3].

MAP2K1 is altered in 2.17% of non-hodgkin lymphoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MAP2K1 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

MAP2K2 is altered in 0.91% of non-hodgkin lymphoma patients [2].

MAP2K2 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MAP2K2 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

MAP2K4 is altered in 1.12% of non-hodgkin lymphoma patients [2].

MAP2K4 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MAP2K4 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

MAP3K1 is altered in 0.99% of non-hodgkin lymphoma patients [2].

MAP3K1 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MAP3K1 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

MAPK1 is altered in 1.06% of non-hodgkin lymphoma patients [2].

MAPK1 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain MAPK1 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

MCPH1 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MCPH1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [3].

MDM2 is altered in 0.86% of non-hodgkin lymphoma patients [2].

MDM2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MDM2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MDM4 is altered in 0.53% of non-hodgkin lymphoma patients [2].

MDM4 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MDM4 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MECOM is altered in 2.63% of non-hodgkin lymphoma patients [2].

MECOM is an inclusion eligibility criterion in 20 clinical trials for non-hodgkin lymphoma, of which 13 are open and 7 are closed. Of the trials that contain MECOM status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 8 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (7 open) [3].

MLF1 is an inclusion eligibility criterion in 7 clinical trials for non-hodgkin lymphoma, of which 5 are open and 2 are closed. Of the trials that contain MLF1 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [3].

MLH1 is altered in 0.97% of non-hodgkin lymphoma patients [2].

MLH1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MLH1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MLH3 is altered in 2.97% of non-hodgkin lymphoma patients [2].

MLH3 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MLH3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MLLT1 is an inclusion eligibility criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain MLLT1 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (6 open) [3].

MLLT10 is an inclusion eligibility criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain MLLT10 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (6 open) [3].

MLLT3 is an inclusion eligibility criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain MLLT3 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (6 open) [3].

MLLT4 is an inclusion eligibility criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain MLLT4 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (6 open) [3].

MNX1 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains MNX1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is altered in 1.13% of non-hodgkin lymphoma patients [2].

MRE11A is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MRE11A status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MSH2 is altered in 0.86% of non-hodgkin lymphoma patients [2].

MSH2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MSH2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MSH3 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MSH3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MSH6 is altered in 1.38% of non-hodgkin lymphoma patients [2].

MSH6 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MSH6 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MTOR is altered in 3.09% of non-hodgkin lymphoma patients [2].

MTOR is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain MTOR status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

MUTYH is altered in 0.4% of non-hodgkin lymphoma patients [2].

MUTYH is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain MUTYH status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

MYC is altered in 6.64% of non-hodgkin lymphoma patients [2].

MYC is an inclusion eligibility criterion in 9 clinical trials for non-hodgkin lymphoma, of which 6 are open and 3 are closed. Of the trials that contain MYC status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (2 open) [3].

MYH11 is an inclusion eligibility criterion in 6 clinical trials for non-hodgkin lymphoma, of which 3 are open and 3 are closed. Of the trials that contain MYH11 status and non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (3 open) [3].

NBN is altered in 1.13% of non-hodgkin lymphoma patients [2].

NBN is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain NBN status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

NF1 is altered in 1.77% of non-hodgkin lymphoma patients [2].

NF1 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain NF1 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

NPM1 is altered in 0.45% of non-hodgkin lymphoma patients [2].

NPM1 is an inclusion eligibility criterion in 8 clinical trials for non-hodgkin lymphoma, of which 6 are open and 2 are closed. Of the trials that contain NPM1 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 4 are phase 2 (4 open) [3].

NR4A3 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NR4A3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRAS is altered in 1.3% of non-hodgkin lymphoma patients [2].

NRAS is an inclusion eligibility criterion in 5 clinical trials for non-hodgkin lymphoma, of which 3 are open and 2 are closed. Of the trials that contain NRAS status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [3].

NRIP3 is an inclusion eligibility criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain NRIP3 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 8 are phase 2 (6 open) [3].

NSD1 is altered in 2.45% of non-hodgkin lymphoma patients [2].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is altered in 1.45% of non-hodgkin lymphoma patients [2].

NTRK1 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain NTRK1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

NTRK2 is altered in 1.84% of non-hodgkin lymphoma patients [2].

NTRK2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK2 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

NTRK3 is altered in 0.66% of non-hodgkin lymphoma patients [2].

NTRK3 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

NUP214 is altered in 0.24% of non-hodgkin lymphoma patients [2].

NUP214 is an inclusion eligibility criterion in 17 clinical trials for non-hodgkin lymphoma, of which 10 are open and 7 are closed. Of the trials that contain NUP214 status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (5 open) [3].

NUP98 is altered in 0.79% of non-hodgkin lymphoma patients [2].

NUP98 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is altered in 1.19% of non-hodgkin lymphoma patients [2].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

PARP1 is altered in 0.72% of non-hodgkin lymphoma patients [2].

PARP1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PARP1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

PARP2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PARP2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

PBX1 is an inclusion eligibility criterion in 10 clinical trials for non-hodgkin lymphoma, of which 6 are open and 4 are closed. Of the trials that contain PBX1 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (4 open) [3].

PDGFB is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFB status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is altered in 1.36% of non-hodgkin lymphoma patients [2].

PDGFRA is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain PDGFRA status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

PDGFRB is altered in 1.05% of non-hodgkin lymphoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PHF6 is altered in 1.77% of non-hodgkin lymphoma patients [2].

PHF6 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PHF6 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CA is altered in 0.91% of non-hodgkin lymphoma patients [2].

PIK3CA is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3CA status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

PIK3CG is altered in 0.88% of non-hodgkin lymphoma patients [2].

PIK3CG is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3CG status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

PIK3R1 is altered in 1.65% of non-hodgkin lymphoma patients [2].

PIK3R1 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3R1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

PIK3R2 is altered in 1.08% of non-hodgkin lymphoma patients [2].

PIK3R2 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3R2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

PMS1 is altered in 1.13% of non-hodgkin lymphoma patients [2].

PMS1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PMS1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

PMS2 is altered in 0.93% of non-hodgkin lymphoma patients [2].

PMS2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PMS2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

POLE is altered in 1.62% of non-hodgkin lymphoma patients [2].

POLE is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain POLE status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

PPP2R1A is altered in 1.28% of non-hodgkin lymphoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PPP2R1A status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

PPP2R2A is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain PPP2R2A status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

PRDM16 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PRDM16 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PTEN is altered in 3.05% of non-hodgkin lymphoma patients [2].

PTEN is an inclusion eligibility criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].

RAD50 is altered in 1.28% of non-hodgkin lymphoma patients [2].

RAD50 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RAD50 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

RAD51 is altered in 0.99% of non-hodgkin lymphoma patients [2].

RAD51 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

RAD51B is altered in 0.42% of non-hodgkin lymphoma patients [2].

RAD51B is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RAD51B status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

RAD51C is altered in 0.76% of non-hodgkin lymphoma patients [2].

RAD51C is an inclusion eligibility criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51C status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].

RAD51D is altered in 0.61% of non-hodgkin lymphoma patients [2].

RAD51D is an inclusion eligibility criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain RAD51D status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].

RAD54L is altered in 0.36% of non-hodgkin lymphoma patients [2].

RAD54L is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain RAD54L status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

RAF1 is altered in 0.79% of non-hodgkin lymphoma patients [2].

RAF1 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain RAF1 status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

RB1 is altered in 2.98% of non-hodgkin lymphoma patients [2].

RB1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain RB1 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RET is altered in 1.23% of non-hodgkin lymphoma patients [2].

RET is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR is altered in 1.36% of non-hodgkin lymphoma patients [2].

RICTOR is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain RICTOR status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

ROS1 is altered in 2.64% of non-hodgkin lymphoma patients [2].

ROS1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RPN1 is an inclusion eligibility criterion in 20 clinical trials for non-hodgkin lymphoma, of which 13 are open and 7 are closed. Of the trials that contain RPN1 status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 8 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 9 are phase 2 (7 open) [3].

RPTOR is altered in 1.36% of non-hodgkin lymphoma patients [2].

RPTOR is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain RPTOR status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

RUNX1 is altered in 0.85% of non-hodgkin lymphoma patients [2].

RUNX1 is an inclusion eligibility criterion in 10 clinical trials for non-hodgkin lymphoma, of which 7 are open and 3 are closed. Of the trials that contain RUNX1 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 6 are phase 1 (3 open), and 3 are phase 2 (3 open) [3].

RUNX1T1 is altered in 1.58% of non-hodgkin lymphoma patients [2].

RUNX1T1 is an inclusion eligibility criterion in 6 clinical trials for non-hodgkin lymphoma, of which 3 are open and 3 are closed. Of the trials that contain RUNX1T1 status and non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (3 open) [3].

SLX4 is altered in 5.71% of non-hodgkin lymphoma patients [2].

SLX4 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain SLX4 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

SMARCA4 is altered in 4.34% of non-hodgkin lymphoma patients [2].

SMARCA4 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain SMARCA4 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [3].

SMARCB1 is altered in 1.62% of non-hodgkin lymphoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain SMARCB1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [3].

SRC is altered in 0.07% of non-hodgkin lymphoma patients [2].

SRC is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain SRC status and non-hodgkin lymphoma as inclusion criteria, 3 are phase 2 (2 open) [3].

SS18 is altered in 0.74% of non-hodgkin lymphoma patients [2].

SS18 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains SS18 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

STAG2 is altered in 1.78% of non-hodgkin lymphoma patients [2].

STAG2 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain STAG2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

STK11 is altered in 1.3% of non-hodgkin lymphoma patients [2].

STK11 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain STK11 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].

TCF3 is altered in 1.8% of non-hodgkin lymphoma patients [2].

TCF3 is an inclusion eligibility criterion in 10 clinical trials for non-hodgkin lymphoma, of which 6 are open and 4 are closed. Of the trials that contain TCF3 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (4 open) [3].

TET2 is altered in 11.18% of non-hodgkin lymphoma patients [2].

TET2 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TET2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TFE3 is altered in 0.47% of non-hodgkin lymphoma patients [2].

TFE3 is an inclusion eligibility criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TFE3 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 17.79% of non-hodgkin lymphoma patients [2].

TP53 is an inclusion eligibility criterion in 18 clinical trials for non-hodgkin lymphoma, of which 10 are open and 8 are closed. Of the trials that contain TP53 status and non-hodgkin lymphoma as inclusion criteria, 2 are early phase 1 (1 open), 7 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), and 7 are phase 2 (5 open) [3].

TSC1 is altered in 0.99% of non-hodgkin lymphoma patients [2].

TSC1 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain TSC1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

TSC2 is altered in 2.1% of non-hodgkin lymphoma patients [2].

TSC2 is an inclusion eligibility criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain TSC2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].

WHSC1 is altered in 2.86% of non-hodgkin lymphoma patients [2].

WHSC1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain WHSC1 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (2 open) [3].

WT1 is altered in 1.04% of non-hodgkin lymphoma patients [2].

WT1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain WT1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].

XRCC1 is altered in 1.08% of non-hodgkin lymphoma patients [2].

XRCC1 is an inclusion eligibility criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain XRCC1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [3].